ORYZON GENOMICS news, videos and press releases - Page 2
For more news please use our advanced search feature.
ORYZON GENOMICS - More news...
ORYZON GENOMICS - More news...
- ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
- ORYZON to Give Updates on Corporate Progress in February-March
- ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
- ORYZON to Give Updates on Corporate Progress in January
- ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
- ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022
- ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)
- ORYZON to Give Updates on Corporate Progress in November
- ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022
- ORYZON to Give Updates on Corporate Progress in October
- ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
- ORYZON Collaborates with the CMT Research Foundation in the US
- ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
- ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers
- ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €20 Million Over 30 Months
- ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML
- ORYZON Announces FDA Orphan Drug Designation Granted to Iadademstat for Treatment of Small Cell Lung Cancer
- ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia
- ORYZON to Give Updates on Corporate Progress in June
- ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022
- Edison Investment Research Limited: Oryzon Genomics (ORY): Planning iadademstat's path to market
- Oryzon Genomics (ORY): Planning Iadademstat's Path to Market
- Oryzon Genomics – Edison Open House interview
- Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)
- Edison Issues Outlook On Oryzon Genomics (ORY)
- ORYZON to Present First Clinical Data from ALICE Phase IIa Trial with Iadademstat at the 24th Congress of the European Hematology Association
- ORYZON Announces First Patient in the US in ETHERAL-US: A Phase IIa Clinical Trial with Vafidemstat in Alzheimer's Disease
- ORYZON Receives $1.5 Million Grant from Alzheimer's Drug Discovery Foundation (ADDF)
- ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2019